AVLN vs CGEM
AVLN: Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases. CGEM: Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
Side-by-side fundamentals
| Metric | AVLN | CGEM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $28.72 | $17.65 | |
| Market cap as of 2026-07-23 | $1.3B | $1.1B | |
| PEG as of 2026-07-23 | n/a | -0.24 | |
| Net margin as of 2026-07-23 | n/a | -346.2% | |
| Operating margin as of 2026-07-23 | n/a | -358.8% | |
| ROE as of 2026-07-23 | -63.8% | -51.4% | CGEM higher |
| ROA as of 2026-07-23 | -57.2% | -47.6% | CGEM higher |
| Debt / equity as of 2026-07-23 | 0.14 | 0.00 | CGEM lower |
| Beta as of 2026-07-23 | -0.12 | 0.00 | |
| 1-year return as of 2026-07-22 close | -1.6% | +140.2% | CGEM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.